ATE308335T1 - Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese - Google Patents

Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese

Info

Publication number
ATE308335T1
ATE308335T1 AT02733167T AT02733167T ATE308335T1 AT E308335 T1 ATE308335 T1 AT E308335T1 AT 02733167 T AT02733167 T AT 02733167T AT 02733167 T AT02733167 T AT 02733167T AT E308335 T1 ATE308335 T1 AT E308335T1
Authority
AT
Austria
Prior art keywords
hrgp
histidine
polypeptides
rich glycoprotein
inhibit angiogenesis
Prior art date
Application number
AT02733167T
Other languages
English (en)
Inventor
Lena Claesson Welsh
Helena Larsson
Anna-Karin Olsson
Original Assignee
Innoventus Project Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innoventus Project Ab filed Critical Innoventus Project Ab
Application granted granted Critical
Publication of ATE308335T1 publication Critical patent/ATE308335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02733167T 2001-02-05 2002-02-04 Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese ATE308335T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26650501P 2001-02-05 2001-02-05
PCT/IB2002/002425 WO2002076486A2 (en) 2001-02-05 2002-02-04 Histidine-rich glycoprotein

Publications (1)

Publication Number Publication Date
ATE308335T1 true ATE308335T1 (de) 2005-11-15

Family

ID=23014841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733167T ATE308335T1 (de) 2001-02-05 2002-02-04 Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese

Country Status (8)

Country Link
US (2) US7205392B2 (de)
EP (1) EP1357930B1 (de)
JP (1) JP2004527242A (de)
AT (1) ATE308335T1 (de)
CA (1) CA2436340A1 (de)
DE (1) DE60207043T2 (de)
ES (1) ES2252461T3 (de)
WO (1) WO2002076486A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2252461T3 (es) 2001-02-05 2006-05-16 Innoventus Project Ab Glicoproteina rica en histidina (hrgp) para la inhibicion de la angiogenesis.
EP1365804A4 (de) * 2001-02-14 2004-09-08 Attenuon Llc Histidinprolin-reiches glycoprotein (hprg) als antiangiogenes und antitumorales mittel
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
SE0301988D0 (sv) * 2003-07-07 2003-07-07 Innoventus Project Ab Active subfragment of an endogenous peptide
CN102895663A (zh) 2004-04-14 2013-01-30 健泰科生物技术公司 含有用于调节血管发育的egfl7拮抗剂的组合物及方法
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2011123041A1 (en) * 2010-04-01 2011-10-06 Karolinska Institutet Innovation Ab Fertilization prediction and promotion
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
EP2859898B1 (de) * 2012-06-06 2021-03-17 National University Corporation Okayama University Therapeutikum und testverfahren für erkrankungen im zusammenhang mit der aktivierung von neutrophilen
US9696321B2 (en) 2012-06-06 2017-07-04 National University Corporation Okayama University Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN111182908A (zh) 2017-08-03 2020-05-19 大塚制药株式会社 药物化合物及其纯化方法
US20210198317A1 (en) 2018-05-31 2021-07-01 National University Corporation Okayama University Reactive oxygen production inhibitor and/or scavenging promoter
EP3815706A4 (de) 2018-06-28 2022-03-16 National University Corporation Okayama University Mittel zur verbesserung der phagozytosefähigkeit von neutrophilen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5133866A (en) 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
JPH0753757B2 (ja) * 1988-08-12 1995-06-07 寳酒造株式会社 モノクローナル抗体及びその使用方法
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
JP2003528035A (ja) 1999-10-01 2003-09-24 アングストロム ファーマシューティカルズ， インコーポレイテッド ｕＰＡおよびｕＰＡＲを標的化する診断プロ−ブおよび治療薬
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
AU2001227679A1 (en) 2000-02-25 2001-09-03 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
JP2004515222A (ja) 2000-07-24 2004-05-27 アテニュオン， エルエルシー ヒトキニノゲンｄ５ドメインポリペプチドおよびこれらの使用
WO2002069885A2 (en) 2001-01-19 2002-09-12 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods for treating brain tumors and other diseases
ES2252461T3 (es) 2001-02-05 2006-05-16 Innoventus Project Ab Glicoproteina rica en histidina (hrgp) para la inhibicion de la angiogenesis.
EP1365804A4 (de) 2001-02-14 2004-09-08 Attenuon Llc Histidinprolin-reiches glycoprotein (hprg) als antiangiogenes und antitumorales mittel

Also Published As

Publication number Publication date
DE60207043D1 (de) 2005-12-08
DE60207043T2 (de) 2006-07-13
US7563765B2 (en) 2009-07-21
ES2252461T3 (es) 2006-05-16
US7205392B2 (en) 2007-04-17
EP1357930B1 (de) 2005-11-02
JP2004527242A (ja) 2004-09-09
CA2436340A1 (en) 2002-10-03
WO2002076486A3 (en) 2003-04-17
WO2002076486A2 (en) 2002-10-03
US20050042201A1 (en) 2005-02-24
EP1357930A2 (de) 2003-11-05
US20020165131A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
ATE308335T1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
DE69936105D1 (de) Menschliche tslp nukleinsäuren und polypeptide
DE69926480D1 (de) Acpl dna und polypeptide
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
NO20063026L (no) Antistoffer
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
HRP20050024A2 (en) Pegylated t20 polypeptide
CY1107594T1 (el) DNA ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ IL-1η
DE60118359D1 (de) Humanische pellino-polypeptide
CA2380216A1 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
DE60214676D1 (de) Hochaffine antagonisten der elr-cxc chemokine
DE60219215D1 (de) Prionen-bindende peptidsequenzen
MXPA04004564A (es) Genes que codifican receptores acoplados a proteinas g y metodos de uso de los mismos.
NO331197B1 (no) Fremgangsmate for a identifisere forbindelser som binder til EDG8-polypeptid
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
ATE442444T1 (de) Glykosylphosphatidylinositolhaltige polypeptide
ATE441865T1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
ATE443715T1 (de) Polypeptide aus haemophilus influenza
DE10394174D2 (de) Peptide mit hohem Cysteingehalt
AU2003260546A8 (en) Device for the presentation of peptides or proteins, method for the preparation and use thereof
DE60039303D1 (de) Immunogene polypeptide aus moraxella catarrhalis und deren verwendungen
BRPI0216042B8 (pt) polipeptídeo capaz de se ligar a ang-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.
ATE459640T1 (de) Sich an die protein phosphatase 2a bindende peptide und sie kodierende polynukleotide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties